-
T-Mobile to Buy Most of US Cellular for $4.4 Billion; Court to Hear TikTok Ban Challenges in Sept. | Business Matters Full Broadcast (May 28) -
J&J Tops 4th-Quarter Earnings Forecasts as Profit, Revenue Slip
-
J&J’s Cancer Drug Sales Help Weather Hit From Stronger Dollar
-
Contract Manufacturer Emergent Says J&J Breached Vaccine Contract
-
J&J Sues to Block Sales of ‘Dangerous’ Counterfeit HIV Drugs
-
J&J Suspends Sales Forecast for COVID Vaccine Citing Uncertainty in Demand, Global Supply Surplus
-
EU Regulator Backs Giving J&J Booster Shot to Adults 2 Months After Initial Dose
-
Wall Street Powers Higher on J&J, Big Tech Boost
-
US Judge Halts Johnson & Johnson Talc Litigation for 60 Days
-
Oklahoma Court Overturns $465 Million Opioid Judgment Against J&J
-
J&J Settles Most Risperdal Lawsuits, With $800 Million in Expenses
-
J&J Says COVID-19 Booster Dose Increases Antibody Levels ‘Nine-Fold’
-
J&J CEO Gorsky to Step Down, Company Veteran to Lead in 2022
-
J&J Recalls Sunscreens After Carcinogen Found in Some Sprays
-
Germany Demands J&J Make Up Likely Millions of Lost COVID-19 Vaccine Shots for July
-
Johnson & Johnson COVID-19 Vaccine Use Should Resume: CDC Advisers
-
J&J to Cooperate in Study of Rare Blood Clots Linked to CCP Virus Vaccine
-
7th Case of Rare, Severe Blood Clot Linked to J&J Vaccine
-
CDC Vaccine Advisory Committee Says J&J COVID-19 Vaccine to Remain on Pause
-
CDC Investigates Death of Woman Who Took J&J Vaccine
-
Fauci Says J&J Vaccine Pause Will Only Last ‘Days to Weeks,’ Rather Than Months
-
Pentagon Halts Usage of COVID-19 Vaccine on Military: Official
-
J&J Takes Over Baltimore Vaccine Plant Where 15 Million Doses Were Contaminated
-
Johnson & Johnson Asks for Emergency Use Authorization of Its COVID-19 Vaccine
-
AstraZeneca Resumes COVID-19 Vaccine Trial in US, J&J to Follow
-
Johnson & Johnson Announces Start of Phase 3 Trials for CCP Virus Vaccine
-
J&J Loses Bid to Overturn Baby Powder Verdict, but Damages Cut to $2.12 Billion
